Viatris Inc (VTRS)vsZoetis Inc (ZTS)
VTRS
Viatris Inc
$16.43
+0.86%
HEALTHCARE · Cap: $20.45B
ZTS
Zoetis Inc
$72.66
-5.97%
HEALTHCARE · Cap: $31.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 53% more annual revenue ($14.56B vs $9.53B). ZTS leads profitability with a 28.0% profit margin vs -2.0%. VTRS appears more attractively valued with a PEG of 1.12. ZTS earns a higher WallStSmart Score of 66/100 (B-).
VTRS
Hold48
out of 100
Grade: D+
ZTS
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for VTRS.
Margin of Safety
+10.8%
Fair Value
$144.23
Current Price
$72.66
$71.57 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Every $100 of equity generates 82 in profit
Strong operational efficiency at 36.6%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
ROE of -2.0% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Expensive relative to growth rate
Trading at 9.3x book value
2.9% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : VTRS
The strongest argument for VTRS centers on Price/Book. PEG of 1.12 suggests the stock is reasonably priced for its growth.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.0% and operating margin at 36.6%.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.86 is elevated, increasing financial risk.
Key Dynamics to Monitor
VTRS profiles as a turnaround stock while ZTS is a value play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.90 — expect wider price swings.
VTRS is growing revenue faster at 8.1% — sustainability is the question.
VTRS generates stronger free cash flow (348M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (66/100 vs 48/100), backed by strong 28.0% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?